Market Overview

UPDATE: BMO Capital Markets Raises PT on Isis Pharmaceuticals Following Development Head Meeting

Related ISIS
Benzinga's Top Initiations
Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antisense Drugs FOr Cardiovascular, Metabolic And Renal Disease

In a report published Friday, BMO Capital Markets analyst Jim Birchenough reiterated an Outperform rating on Isis Pharmaceuticals (NASDAQ: ISIS), and raised the price target from $22.00 to $31.00.

In the report, Birchenough noted, “The BMO Capital Markets US biotechnology team hosted a meeting this week with Isis Pharmaceuticals SVP of Clinical Development Dr. Richard Geary. Focus of the meeting was on a burgeoning pipeline of antisense oligonucleotide (ASO) therapeutics following recent approval of its first ASO therapeutic KYNAMRO. With 28 different ASO therapeutics in development, primary focus was on key late stage programs including wholly owned ISISApoC3-Rx for severe triglyceride elevation as well as partnered programs for ISIS-SMN-Rx for spinal muscular atrophy (SMA) and TTR associated familial amyloid polyneuropathy (FAP).”

Isis Pharmaceuticals closed on Thursday at $19.41.

Latest Ratings for ISIS

Sep 2015BarclaysInitiates Coverage onEqual-weight
Jun 2015NeedhamReiteratesBuy
Jun 2015JP MorganMaintainsNeutral

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings


Related Articles (ISIS)

Get Benzinga's Newsletters